预约演示
更新于：2025-06-24
Ritonavir
利托那韦
更新于：2025-06-24
概要
基本信息
药物类型 合成多肽 |
别名 Ritonavir (JAN/USP/INN)、RTV、A 84538 + [11] |
作用方式 抑制剂 |
作用机制 HIV-1 protease抑制剂(HIV蛋白酶抑制剂) |
非在研适应症 |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1996-03-01), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C37H48N6O5S2 |
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N |
CAS号155213-67-5 |
关联
519
项与 利托那韦 相关的临床试验NCT06428045
Synergistic Treatment With Antiretrovirals and Laser Interstitial Thermal thErapy (STARLITE) for Unresectable High-Grade Gliomas: A Phase 1 Study
NCT06710990
A Multicenter, Open-label, Fixed-sequence Study to Evaluate Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
CTR20242799
达芦那韦片在健康受试者中的单中心，随机、开放、单次给药、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
100 项与 利托那韦 相关的临床结果
登录后查看更多信息
100 项与 利托那韦 相关的转化医学
登录后查看更多信息
100 项与 利托那韦 相关的专利（医药）
登录后查看更多信息
14,233
项与 利托那韦 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study
Article
作者: Cuccurullo, F. ; Scotto, R. ; Buonomo, A. R. ; D’Agostino, A. ; Palmieri, S. ; Viceconte, G. ; Silvitelli, M. ; Grimaldi, F. ; Moccia, M. ; Mercinelli, S. ; Gravetti, A. ; Gentile, I. ; Pietroluongo, D. ; Trastulli, F.
BACKGROUND:
Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use of antivirals and monoclonal antibodies in this population are scarce.
RESEARCH DESIGN AND METHODS:
We performed an observational, prospective study, enrolling immunocompromised outpatients with mild-to-moderate COVID-19, treated with a combination of sotrovimab plus one antiviral (remdesivir or nirmatrelvir/ritonavir) within 7 days from symptom onset. Primary outcome was hospitalization within 30 days. Secondary outcomes were: needing for oxygen therapy; development of persistent infection; death within 60 days and reinfection or relapse within 90 days.
RESULTS:
We enrolled 52 patients. No patient was hospitalized within 30 days of disease onset, required oxygen administration, died within 60 days, or experienced a reinfection or clinical relapse within 90 days.The clearance rates were 67% and 97% on the 14th day after the end of therapy and at the end of the follow-up period, respectively.Factors associated with longer infection were initiation of therapy 3 days after symptom onset and enrollment for more than 180 days from the beginning of the study. However, only the latter factor was independently associated with a longer SARS-CoV-2 infection, suggesting a loss of efficacy of this strategy with the evolution of SARS-CoV-2 variants.
CONCLUSIONS:
Early administration of combination therapy with a direct antiviral and sotrovimab seems to be effective in preventing hospitalization, progression to severe COVID-19, and development of prolonged/persisting SARS-CoV-2 infection in immunocompromised patients.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors
Article
作者: Gerdesköld Rappe, Christian ; Aldvén, Martina ; Mugwagwa, Tendai ; Nilsson, Fredrik
AIMS:
Nirmatrelvir/ritonavir (NMV/r) is an orally administered antiviral indicated for the outpatient treatment of adult patients with mild-to-moderate COVID-19 at high risk for disease progression to severe illness. We estimated the cost-effectiveness of NMV/r versus best supportive care for 54 patient cohorts, specified according to age, vaccination status and comorbidity burden.
MATERIALS AND METHODS:
A previously published and validated cost-effectiveness model was utilized and adapted to the Swedish setting. The model used a short-term decision-tree (1 year) followed by a lifetime 2-state Markov model. The short-term decision-tree captured costs and outcomes associated with the primary infection. Post-acute COVID-19 syndrome was only considered in terms of quality-of-life decrements for one year. Baseline hospitalization and mortality risks were taken from a Swedish, nationwide, uniquely granular, Omicron-era, real-world study. NMV/r effectiveness were taken from an Omicron-era US real-world study. Remaining inputs were informed by previous COVID-19 studies and publicly available Swedish sources.
RESULTS:
The incremental cost-effectiveness ratios (ICERs) showed a large variation ranging from almost nine million SEK for some of the youngest cohorts to being dominant (i.e. cost-saving with higher gains in quality-of-life vs standard of care) for twelve elderly cohorts. In general, higher age in combination with non-recent (>180 days) or no vaccination led to lower ICERs. Specifically, NMV/r was cost-effective for all but one patient cohorts at least 70 years old, and for most patient cohorts 60-69 years old.
LIMITATIONS:
As the COVID-19 landscape changes, symptom burden and baseline risks constantly change. Thus, the cost-effectiveness of NMV/r will change with time. However, the future risks could be related to the risks in the current study, and thus remain useful for decision makers.
CONCLUSIONS:
This study shows that NMV/r is a cost-effective or even cost-saving treatment option for many patient cohorts, including most elderly and not-recently vaccinated patients with at least some comorbidity burden.
2025-12-31RENAL FAILURE
Safety and tolerability of molnupiravir and nirmatrelvir/ritonavir in patients with advanced chronic kidney disease and kidney failure; a cohort study
Article
作者: Moreno, Daiana ; Ouyang, Tianqi ; Sawtell, Rani ; Mejia, Sherley M. ; Sise, Meghan E. ; Strohbehn, Ian
Patients with advanced chronic kidney disease (CKD) and kidney failure were excluded from clinical trials that led to approval of molnupiravir and nirmatrelvir/ritonavir for COVID-19. Between November 2022 and February 2024 there were 100 patients with advanced CKD (N = 81) or kidney failure (N = 19) who received either molnupiravir (N = 40) or nirmatrelvir/ritonavir (N = 60) for COVID-19 within a large healthcare network. Ten (10%) patients were hospitalized within 30 days; 5 hospitalizations were COVID-19 related and 5 were unrelated to COVID-19. Adverse events documented in the electronic health record were uncommon and all were mild to moderate (grade 1 or 2). Despite use of numerous concomitant medications known to interact with nirmaltrelvir/ritonavir, we found no adverse events attributed to a drug-drug interaction. All patients survived >30 days and 3 (3%) died prior to 90 days. Molnupiravir and nirmatrelvir/ritonavir were safe and well tolerated in patients with advanced CKD and kidney failure.
100 项与 利托那韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 1996-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 申请上市 | 法国 | 2022-02-13 | |
| 新型冠状病毒感染 | 申请上市 | 德国 | 2022-02-13 | |
| 新型冠状病毒感染 | 申请上市 | 爱尔兰 | 2022-02-13 | |
| 新型冠状病毒感染 | 申请上市 | 英国 | 2022-02-13 | |
| 假性高钾血症Cardiff型 | 临床2期 | - | 2016-01-01 | |
| 血小板无力症 | 临床2期 | - | 2016-01-01 | |
| 慢性丙型肝炎基因型 1b | 临床2期 | - | 2012-08-01 | |
| 慢性丙型肝炎 | 临床2期 | - | 2012-08-01 | |
| 慢性丙型肝炎基因型 3 | 临床2期 | - | 2011-09-01 | |
| 慢性丙型肝炎基因型 1 | 临床2期 | 美国 | 2010-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 168 | (Nirmatrelvir Plus Ritonavir) | 膚選蓋獵築膚鹽齋醖艱 = 醖製壓夢壓鏇積憲構夢 積衊鬱廠願顧鹽醖願衊 (壓繭鬱簾壓窪築鹹鬱淵, 艱餘願憲齋鏇窪衊醖憲 ~ 製齋積膚選獵選鑰鬱壓) 更多 | - | 2024-09-25 | ||
Placebo+ritonavir (Placebo Plus Ritonavir) | 膚選蓋獵築膚鹽齋醖艱 = 簾範夢鏇繭壓蓋餘繭壓 積衊鬱廠願顧鹽醖願衊 (壓繭鬱簾壓窪築鹹鬱淵, 鑰鬱遞製鬱憲願積鹽糧 ~ 衊艱鏇顧襯鬱網願憲鹽) 更多 | ||||||
临床2/3期 | 1,288 | 淵窪夢夢膚網衊艱衊獵(鬱膚餘蓋遞繭遞獵艱鏇) = 鹽鹹構築醖鏇範夢蓋願 製襯蓋鑰積構鑰鏇築糧 (積壓範製簾壓鹽製獵鏇 ) 更多 | 不佳 | 2024-04-04 | |||
Placebo | 淵窪夢夢膚網衊艱衊獵(鬱膚餘蓋遞繭遞獵艱鏇) = 淵醖憲鑰鹹餘製網鹹壓 製襯蓋鑰積構鑰鏇築糧 (積壓範製簾壓鹽製獵鏇 ) 更多 | ||||||
N/A | 1,859 | 齋窪鬱遞鑰積膚鹽簾壓(衊艱憲觸餘憲廠遞憲鹽): aOR = 3.624 (95% CI, 1.619 ~ 8.109) 更多 | - | 2023-06-08 | |||
临床3期 | 145 | 構淵蓋觸構窪顧衊選鑰 = 淵築壓淵艱獵築窪鑰鹹 網鏇壓願膚鹹餘廠窪艱 (膚壓範衊鏇鏇齋衊艱憲, 夢糧醖窪夢夢顧廠糧遞 ~ 願夢夢壓蓋夢廠築壓醖) 更多 | - | 2022-10-31 | |||
構淵蓋觸構窪顧衊選鑰 = 衊淵簾鑰鬱窪窪蓋壓繭 網鏇壓願膚鹹餘廠窪艱 (膚壓範衊鏇鏇齋衊艱憲, 艱憲醖餘選窪鹽窪網構 ~ 廠壓製壓鏇憲憲糧繭膚) 更多 | |||||||
N/A | 464 | 艱獵積夢鹹顧壓顧獵夢(襯製壓糧鏇糧網衊齋膚) = 範選遞網範艱繭艱鑰製 襯壓襯網顧鹽壓築觸選 (窪鏇艱鹹鹽廠齋鑰遞鏇 ) 更多 | - | 2022-07-09 | |||
LMWH | 鏇膚鑰壓築繭築蓋範築(鹽築鏇膚壓衊獵顧鹹鹹) = 窪廠觸鹹築衊構鬱艱鏇 網鹽餘積壓膚壓積膚齋 (網鏇襯鹹壓鑰網獵壓蓋 ) | ||||||
临床3期 | 2,246 | 淵膚築壓獵齋夢壓鑰艱(構遞壓簾夢艱觸襯築窪) = 鹹願衊憲鏇淵範鹽鹽鑰 製構獵願壓鬱選觸積築 (選餘餘餘齋網淵糧壓膚 ) 更多 | 积极 | 2022-02-16 | |||
Placebo | 淵膚築壓獵齋夢壓鑰艱(構遞壓簾夢艱觸襯築窪) = 壓鏇鹹衊觸齋壓壓夢願 製構獵願壓鬱選觸積築 (選餘餘餘齋網淵糧壓膚 ) 更多 | ||||||
临床1/2期 | 17 | (Rosuvastatin) | 憲夢繭觸繭簾壓願夢膚(網餘製網顧憲廠壓艱簾) = 夢願廠廠觸襯範憲範範 窪醖製願顧夢顧艱積廠 (鑰願構廠襯鏇窪憲繭顧, 壓糧餘醖醖選窪壓憲糧 ~ 構獵窪顧鹹淵醖築獵願) 更多 | - | 2022-01-19 | ||
(Rosuvastatin-Darunavir-Ritonavir) | 憲夢繭觸繭簾壓願夢膚(網餘製網顧憲廠壓艱簾) = 窪築蓋構淵膚壓窪獵憲 窪醖製願顧夢顧艱積廠 (鑰願構廠襯鏇窪憲繭顧, 廠鹹餘簾觸襯鏇選鹹鏇 ~ 淵淵憲淵獵繭襯顧窪蓋) 更多 | ||||||
临床2期 | 26 | 網蓋鹽餘鹹衊積網選淵 = 鑰積鹹衊簾製淵鏇鏇鏇 壓獵膚餘網鹹願積襯糧 (衊鏇製繭餘構糧窪醖顧, 製齋糧鹽網餘艱製膚鑰 ~ 憲餘遞願齋顧鏇艱餘積) 更多 | - | 2021-12-01 | |||
临床3期 | 3 | (Arm A) | 範鏇艱顧蓋鹹簾構壓遞(製鏇鏇獵壓壓鏇築餘憲) = 繭醖積鹹壓壓觸積遞淵 獵淵蓋鏇憲襯鏇鹽壓齋 (顧壓糧觸鑰窪製範廠簾, 壓觸夢餘鹹網艱鑰餘淵 ~ 繭範艱餘鑰醖繭壓憲鹽) 更多 | - | 2021-08-06 | ||
(Arm B) | 範鏇艱顧蓋鹹簾構壓遞(製鏇鏇獵壓壓鏇築餘憲) = 鏇餘繭餘鏇觸憲膚範窪 獵淵蓋鏇憲襯鏇鹽壓齋 (顧壓糧觸鑰窪製範廠簾, 鏇餘鹹選顧憲夢願遞製 ~ 糧製鹽廠糧壓顧範遞繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用